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Combining Combinatorial Chemistry and Affinity
Chromatography: Highly Selective Inhibitors of
Human Betaine: Homocysteine S-Methyltransferase
combinatorial techniques. The problem with these ap-
proaches is that they generally use only one protein
target. Given the high number of proteins in mammalian
organisms, high-throughput screening procedures have
been developed to handle this complicated task [6, 7].
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as methods of choice to identify new protein-ligand in-
teractions [7, 11–13] (and the references herein). These
methods allow real time recording of ligand-protein in-Summary
teractions and subsequent elution of these complexes
can be used for protein identification by mass spec-A new method to find novel protein targets for ligands
trometry.of interest is proposed. The principle of this approach
However, rather than employ one of these sophisti-is based on affinity chromatography and combinatorial
cated approaches to discover novel protein-ligand inter-chemistry. The proteins within a crude rat liver homog-
actions, we designed a simpler method based on affinityenate were allowed to interact with a combinatorial
capture principles coupled to combinatorial chemistry.library of phosphinic pseudopeptides immobilized on
This approach is not intended to replace various chip-affinity columns. Betaine: homocysteine S-methyl-
based technologies, but the advantage of our methodtransferase (BHMT) was one of the proteins that was
is that it is simple and that a diverse range of chemistryretained and subsequently eluted from these supports.
can be applied on the appropriate resin supports. Al-The phosphinic pseudopeptides, which served as im-
though the immobilization of ligands on chips has mademobilized ligands for the isolation of rat BHMT, were
significant progress, the flexibility of the chemistry thatthen tested for their ability to inhibit human recombi-
can be applied to chips is still far behind that which isnant BHMT in solution. The most potent inhibitor also
possible to apply on standard solid support resins. Webehaved as a selective ligand for the affinity purifica-
anticipated that the recently developed solid supportstion of BHMT from a complex media. Further optimiza-
that are compatible with both organic synthesis andtion uncovered Val-Phe-[PO2-CH2]-Leu-His-NH2 as a
affinity chromatography would be useful for our method-potent BHMT inhibitor that has an IC50 of about 1 M.
ology [14–17]. These new supports make it possible to
prepare affinity columns harboring libraries of diverse
Introduction ligands rather than a single affinity ligand. This feature
considerably extends the capacity of such supports to
The challenge of functional genomics and proteomics selectively isolate interacting proteins from crude prepa-
is to translate sequencing data into a precise under- rations. These aspects, in addition to our observation
standing of how proteins function in cells, tissues, or that few investigators have applied standard combinato-
the whole organism [1–3]. rial chemistry in the field of affinity chromatography, led
Small ligands that are able to specifically interact with us to develop this project.
proteins can be very effective tools in the search for For this study, phosphinic pseudopeptides (pseudo-
proteome function [4, 5]. The classical approaches for peptides phosphinates) were selected as potential li-
the identification of new protein ligands include struc- gands. We previously reported a convenient method to
ture activity studies, molecular computer modeling, or prepare libraries of such compounds [18–20]. Phosphi-
nic pseudopeptides have been shown to function as
transition state analogs of zinc metalloproteases and*Correspondence: jiracek@uochb.cas.cz
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these compounds are highly potent inhibitors of this N-Terminal Sequencing of Proteins P1–P20
The results of the N-terminal sequencing of proteinsprotein family [21]. Given the ability of the phosphoryl
P1–P20 are shown in Table 1. Protein bands P1–P7,group to interact with zinc atoms [22], we anticipated
P11, P12, and P14–P16 revealed no peptide sequence,that phosphinic peptides might also interact with other
probably due to a blocked N-terminus or simply too littlezinc metalloenzymes that do not belong to this family
protein for detection.of zinc proteases [23]. To test this idea, we prepared
Protein P8 was identified as 3-hydroxy-3-methylglu-affinity columns harboring 361 different phosphinic pep-
taryl-CoA synthase (EC 4.1.3.5) [24], protein P13 astides and used them to isolate all interacting proteins
3,2-enoyl-CoA isomerase (EC 5.3.3.8), protein P17 asfrom crude rat liver homogenates. Then, by applying a
L-3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35), anddeconvolution process, we identified the most specific
protein band P18 was identified as enoyl-CoA hydrataseligand within the phosphinate peptide library that had
1 (ECH, EC 4.2.1.17) [25]. These proteins are enzymesthe highest affinity toward one newly discovered protein
involved in the mitochondrial/peroxisomal fatty acidtarget, betaine: homocysteine S-methyltransferase (BHMT).
metabolism and some studies indicate that they couldThis ligand was then used to prepare highly selective
be components of a liver multifunctional enzyme/com-affinity column for BHMT. Furthermore, the ligand was
plex [26].also used as the parent structure to rationally develop
Band P9 was identified as rat elongation factor-1 new and more potent inhibitors of this enzyme.
(lacking residues 1–32), a protein that fulfills an essential
cellular function in protein synthesis in that it binds
charged tRNA molecules and transports them to theResults
acceptor site on the ribosome [27].
The N-terminal sequencing of protein P10 resultedAffinity Chromatography of Proteins from Soluble
in a peptide sequence APIAGKKAKRGI. This sequenceRat Liver Homogenate on Columns Grafted with
matched with the N-terminal sequence (N-terminal MetPhosphinic Pseudopeptide Mixtures of the
is missing) of rat liver betaine: homocysteine S-methyl-General Formula Ac-Xaa-DL-Ala-[PO2-CH2]-
transferase (BHMT, EC 2.1.1.5). BHMT is a cytoplasmicDL-Leu-Xaa-(Ala)2-PL-PEGA
Zn-metalloenzyme responsible for the transfer of methylAll 19 different affinity supports having the general for-
group from betaine to L-homocysteine giving dimethyl-mula Ac-Xaa-DL-Ala-[PO2-CH2]-DL-Leu-Xaa-(Ala)2-PL-
glycine and L-methionine [28, 29].PEGA and Ac-(Ala)2-PL-PEGA (blank resin, BL) were
Protein bands P19 and P20 probably belong to differ-prepared as described in Experimental Procedures.
ent isoforms of rat glutathione S-transferase (GST, TableEach support had an equimolar mixture of 19 protein-
1) [30, 31]. GSTs are widely distributed and abundantogenic amino acids in the Xaa position and a unique
enzymes responsible for the detoxification of endo- andand different amino acid in the Xaa position (Cys was
exogenous electrophiles via their conjugation to the re-omitted). Soluble homogenate from rat livers was pre-
duced glutathione.pared and applied to each support and BL resin to per-
form affinity chromatography. After interaction with pro-
Inhibition Assays of ECH and GST with Solubleteins, washing steps and elutions were performed on
Phosphinic Pseudopeptide Librarieseach support with either the corresponding mixture of
Specific elution of ECH (P18) and GST (P19) with solublesoluble phosphinic pseudopeptides or guanidine hydro-
inhibitors (Figures 1A and 1B, e.g., lines W-i or S-i) ledchloride (GnCl). BL resin was eluted only with GnCl.
us to determine if ECH and GST interactions with theEluted proteins were analyzed by electrophoresis.
affinity columns involved the active sites of these en-
Figure 1 shows electrophoretic analysis of fractions
zymes. To do this, inhibition experiments were per-
obtained from supports with amino acids Trp, Tyr, Phe,
formed with the different soluble pseudopeptide mix-
Met (Figure 1A), and Pro, Ser, Thr, Lys, Arg (Figure 1B)
tures. We used bovine liver ECH (crotonase) and
in position Xaa. Proteins eluted from BL resin and proteins crotonoylcoenzyme-A as a substrate, following the pro-
present in RLH are also shown in Figure 1A. Highly selec- tocols described by He and coworkers [32]. The activity
tive and discreet protein elution was observed when of rat liver GST was determined using glutathione and
affinity columns were eluted with the different mixtures 1-chloro-2,4-dinitrobenzene as substrates [33]. Some
of phosphinic peptides (e.g., lines W-i, F-i, P-i, S-i, Fig- experiments were preformed using the relatively pure
ures 1A and 1B). However, other proteins still remained and enzymatically active preparations of both enzymes
immobilized on columns after elution with soluble phos- obtained from affinity chromatography (e.g., inhibitor-
phinic pseudopeptide mixtures as demonstrated by the eluted fractions W-i or S-i shown in Figure 1, band P18/
electrophoretic profiles obtained when columns were ECH, and band P19/theta-GST). All 19 soluble phosphi-
washed with GnCl (e.g., lines W-g, Y-g, P-g, S-g). The nic pseudopeptide sublibraries of general formula Ac-
electrophoretic analysis of samples from the remaining Xaa-DL-Ala-[PO2-CH2]-DL-Leu-Xaa-NH2 were tested in
affinity supports resulted in similar patterns (data not inhibition assays. These pseudopeptide mixtures failed
shown). The density of protein bands and the occur- to inhibit ECH and GST in concentrations up to 400 M.
rence relative to BL fraction were taken into account
when selecting bands for N-terminal sequencing. The Inhibition of Human Recombinant BHMT
proteins labeled P1 to P20 (Figure 1), some of them as with Phosphinic Pseudopeptides
very weak bands, were blotted onto PVDF membranes The fact that BHMT (P10) is a metalloenzyme led to
investigate its interaction with our phosphinic pseudo-and submitted for N-terminal sequencing.
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Figure 1. Electrophoretic Analysis of Fractions Obtained from Affinity Supports Ac-Xaa-DL-Ala-[PO2-CH2]-DL-Leu-Xaa-(Ala)2-PL-PEGA
(A) Electrophoretic analysis of fractions obtained from affinity supports of general formula Ac-Xaa-DL-Ala-[PO2-CH2]-DL-Leu-Xaa-(Ala)2-PL-
PEGA having Trp (W), Tyr (Y), Phe (F), or Met (M) residues in the Xaa position. RLH means rat liver homogenate (5 g of proteins was applied)
and line BL shows proteins eluted from blank resin.
(B) Electrophoretic analysis of fractions obtained from affinity supports with Pro (P), Ser (S), Thr (T), Lys (K), or Arg (R) residues in the Xaa
position. Fractions eluted with soluble inhibitor mixtures are marked as e.g., P-i (where mixture Ac-Pro-DL-Ala-[PO2-CH2]-DL-Leu-Xaa-NH2
was used), fractions eluted with GnCl are marked as e.g., P-g. Fifteen l from each fraction (400 l) were applied on the gel. Molecular weights
of standards (STD) are shown in kDa. Proteins marked P1–P20 were submitted to N-terminal sequencing. For details, see Experimental
Procedures.
peptides. The results of the inhibition assays of human inhibition of BHMT activity by these mixtures strongly
supports the hypothesis that BHMT was immobilizedrecombinant BHMT with soluble phosphinic pseudo-
peptide mixtures are shown in Figure 2. The effective onto the affinity supports through the direct interaction
Table 1. N-Terminal Sequencing of Isolated Proteins
Protein band N-terminal sequence found Protein identified
P1–P7 nd nd
P8 IPPAPLAKTD 3-Hydroxy-3-methylglutaryl-CoA synthase
mitochondrial precursor
(lacking residues 1–38), EC 4.1.3.5
P9 GIDKRTIEKFEK Elongation factor-1 alpha (lacking residues 1-32)
P10 APIAGKKAKRGI Betaine: homocysteine S-methyltransferase
EC 2.1.1.5
P11, P12 nd nd
P13 ATQQDFENAMN Rat homologue of mouse peroxisomal
3,2-Enoyl-CoA isomerase, EC 5.3.3.8
P14–P16 nd nd
P17 KKILIKHVTV L-3-Hydroxyacyl-CoA dehydrogenase
Mitochondrial precursor
(lacking residues 1–22), EC 1.1.1.35
P18 GANFQYIITEKKG Enoyl-CoA hydratase 1, mitochondrial precursor
(lacking residues 1–29), EC 4.2.1.17
P19 GLELYLDLLSQP Glutathione S-transferase
subunit 12, class-theta, EC 2.5.1.18
P20 PMTLGYWDIRG Glutathione S-transferase
chain 4, class-mu, EC 2.5.1.18
P21 APIAGKKAKRGI Betaine: homocysteine S-methyltransferase
EC 2.1.1.5
P22 APAGGPRVKKGILESLD Rat homologue of mouse
betaine: homocysteine S-methyltransferase 2
P23 YVAEKISGQKVNEAAXD Betaine: homocysteine S-methyltransferase
VAEKISGQKVNEAAXDI (lacking residues 1–88 or 1–89), EC 2.1.1.5
Results of N-terminal sequencing of proteins P1–P20 shown in Figure 1 and of proteins P21–P23 shown in Figure 4B. nd means not determined
(due to the N-terminal blocking).
Chemistry & Biology
116
Figure 2. Inhibition of Human Recombinant
BHMT by Soluble Phosphinic Pseudopeptide
Mixtures Ac-Xaa-DL-Ala-[PO2-CH2]-DL-Leu-
Xaa-NH2
Amino acids in the Xaa position are shown in
a single letter code. The mixtures were tested
at 250 M concentration and the values are
means of three independent measurements.
For details, see Experimental Procedures.
between phosphinic ligands and its active site. The level rat BHMT, yielding the same N-terminal sequence as
obtained from protein band P10 of the gel displayedof inhibition of individual inhibitor mixtures at 250 M
concentration varied from 50% to 5%. The presence of in Figure 1B. This identity was confirmed by specific
recognition of protein P21 by polyclonal antibodiesnegatively charged residues like Asp or Glu in the Xaa
position resulted in a very poor inhibition. The highest raised against human recombinant BHMT (Figure 4C,
lines B1, H1, and I1). A protein migrating at the sameinhibition was observed with the mixture having Val resi-
due in the Xaa position. This mixture was selected for level was also recognized by the antibodies in the line
loaded with a crude homogenate from rat liver (Figurefurther study.
Subsequently, 19 different phosphinic pseudopep- 4C, RLH). Sequencing of band P22 revealed the se-
quence APAGGPRVKKGILESLD, which is very similartides of general formula Ac-Val-DL-Ala-[PO2-CH2]-DL-
Leu-Xaa-NH2 were prepared. Each pseudopeptide dif- to the N-terminal sequence MAPAGSTRAKKGVLERLDS
of the so-called mouse BHMT 2 [34]. We believe thatfered by having a single and different amino acid in the
Xaa position. The ability of these pseudopeptides to protein P22 is probably the rat homolog of mouse BHMT
2. Sequencing protein P23 gave two sequences (Tableinhibit human recombinant BHMT at 250 M concentra-
tion is displayed in Figure 3. These data revealed a clear 1), apparently shifted by one amino acid. By searching
in the protein databases, we found that protein P23 is thepreference of the enzyme for His residue in the Xaa
position suggesting that Ac-Val-DL-Ala-[PO2-CH2]- degradation product of the rat BHMT lacking N-terminal
residues 1–88 or 1–89. Such a degraded form of BHMTDL-Leu-His-NH2 should behave as a rather selective in-
hibitor of BHMT. has already been described by other authors [35]. Pro-
tein P21 was present as a faint band in fractions eluted
with betaine (lines B1–B2) or with compound Ac-Val-Affinity Purification of Rat Liver BHMT on Ac-Val-
DL-Ala-[PO2-CH2]-DL-Leu-His-AOA-Ala- DL-Ala-[PO2-CH2]-DL-Leu-His-NH2 (lines I1–I2). On
the other hand, three DL-homocysteine elutions (linesDap-Sepharose
The Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His-NH2 pseu- H1–H3) resulted in a thick band P21 (with decreasing
intensity from line H1 to H3) and weaker bands P22 anddopeptide was synthesized stepwise via suitable spacer
on NHS-activated Sepharose (Figure 4A) and used for P23, consistent with the idea that these inhibitors have
high affinity for the homocysteine binding site. Washingaffinity purification of BHMT from crude rat liver homog-
enate as described in Experimental Procedures. Figure the column with sodium dodecylsulfate (SDS) and GnCl
solutions (lines S1, S2 and G1, G2, respectively) revealed4B shows electrophoretic analysis of fractions obtained
from this affinity chromatography. Three major protein that almost no other protein remained on the affinity
column after previous elutions. Overall, these resultsbands labeled P21–P23 were submitted to the N-termi-
nal sequencing (Table 1). Protein P21 was identified as demonstrate that Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-
Figure 3. Inhibition of Human Recombinant
BHMT by Single Soluble Phosphinic Pseudo-
peptides Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-
Xaa-NH2
Amino acids in the Xaa position are shown
by single letter code. The compounds were
tested at 250 M concentration and the val-
ues are means of three independent mea-
surements. For details, see Experimental Pro-
cedures.
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Figure 4. Affinity Purification of Rat Liver BHMT
(A) Structure of affinity matrix used for the isolation of rat liver BHMT.
(B) Electrophoretic analysis of fractions obtained from the affinity support shown above. RLH means rat liver homogenate (20 g of proteins
was applied). Fractions B1–B2 were eluted with betaine, fractions H1–H3 with DL-homocysteine, fractions I1–I2 with a solution of compound
1 (Table 2), fractions S1–S2 with 1% SDS, and fractions G1–G2 with 6 M GnCl. Fifteen l from each fraction (700 l) were applied on the gel.
Molecular weights of standards (STD) are shown in kDa. Proteins marked as P21–P23 were submitted to N-terminal sequencing.
(C) Western blot analysis of selected fractions from affinity purification of rat liver BHMT with polyclonal antibodies against human recombinant
BHMT. For details, see Experimental Procedures.
His-NH2 has high specificity toward BHMT since it was noblot revealed that S-g fraction from Ac-Ser-DL-Ala-
[PO2-CH2]-DL-Leu-Xaa-(Ala)2-PL-PEGA affinity columnable to selectively retain the enzyme on the affinity col-
umn while the other proteins in the crude extract were (5 moles) contained about 4 g of 44 kDa BHMT.
easily washed away.
Optimization of Phosphinic Pseudopeptide
Inhibitors of BHMTEstimate of the Yield of BHMT Purification
We performed densitometric analysis of the immunoblot Several analogs of pseudopeptide Ac-Val-DL-Ala-
[PO2-CH2]-DL-Leu-His-NH2 (compound 1, Table 2) wereshown in Figure 4C to calculate the yield of BHMT. The
data revealed that all BHMT positive fractions obtained synthesized in order to reveal the role of different struc-
tural elements have in insuring the affinity and potencyfrom Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His-AOA-Ala-
Dap-Sepharose affinity column (7 moles was used) of this compound toward BHMT. Given the significant
role of His in position Xaa of compound 1 for the inhibi-should contain about 0.15% of total 44 kDa BHMT pres-
ent in 45 ml of RLH applied. The comparison with the tion of BHMT, we hypothesized that His or Cys residues
in this position might interact directly with the catalyticimmunoblot of pure recombinant human BHMT (not
shown) revealed that all BHMT positive fractions eluted Zn2 ion of BHMT. Both His and Cys side chains are
known as powerful ligands of zinc [36]. However, com-from this column should contain about 130g (3 nmoles)
of 44 kDa BHMT. Additionally, we performed another pound 2, having Cys in the Xaa position, did not inhibit
BHMT at 100 M concentration. Compounds 3 and 4immunoblotting analysis (not shown) of fractions S-g,
T-g, RLH, and BL that are shown in Figures 1A and 1B. are analogs of pseudopeptide 1 with different amino
acid side chains adjacent to the phosphinic moiety andBHMT specific polyclonal antibodies did not detect any
positive band in the BL line. However, 44 kDa BHMT were prepared using available phosphinic pseudopep-
tide precursors [20]. Inhibition potency of compound 3,positive bands were detected in fractions RLH, S-g, and
T-g, which indicates that the interaction was specific to in respect to compound 1, shows that the substitution
of methyl by phenyl residue is very well tolerated bypseudopeptides. The densitometric analysis of the immu-
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the four diastereoisomers for each compound, two ex-Table 2. Inhibition of Human BHMT by Phosphinic
Pseudopeptide Analogs hibit higher affinity for BHMT (compounds 8a, 8b and
9a, 9c), pinpointing the role of the stereochemistry forCompound, 100 M % of Inhibition
the potency of these phosphinic pseudopeptides.
1 Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His-NH2 57.4
2 Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-Cys-NH2 0.0
Determination of IC50 Values of Phosphinic3 Ac-Val-DL-Phe-[PO2-CH2]-DL-Leu-His-NH2 53.7
4 Ac-Val-DL-Phe-[PO2-CH2]-DL-Ala-His-NH2 8.7 Pseudopeptides Val-Phe-[PO2-CH2]-Leu-
5 Ac-Val-Ala-Leu-His-NH2 25.9 His-NH2 toward Human Recombinant BHMT
6 Ac-DL-Ala-[PO2-CH2]-DL-Leu-NH2 0.0 We determined the IC50 values toward human recombi-7 Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His 0.0 nant BHMT for separated diastereoisomers of the most8 Val-DL-Ala-[PO2-CH2]-DL-Leu-His-NH2 70.6
strongly inhibiting compound 9. The results shown in9 Val-DL-Phe-[PO2-CH2]-DL-Leu-His-NH2 80.3
Table 3 demonstrate that all diastereoisomers of com-
Inhibition potencies of phosphinic pseudopeptide analogs at 100
pound 9 are relatively potent inhibitors of BHMT with
M concentration toward human recombinant BHMT. All com-
IC50 values in low micromolar range. Two of the diastere-pounds (with the exception of peptide 5) are mixtures of four diaster-
oisomers, 9a and 9c, are significantly stronger than theeoisomers.
other two. We observed a marked increase in inhibition
when the pH of the buffer was changed from 7.5 to 6.9.
The diastereosomers 9b, 9c, and 9d had IC50 valuesBHMT. In contrast, the substitution of isobutyl side chain
about 20% lower at pH 6.9 than that observed at pH 7.5.(compound 1) by methyl (compound 4) resulted in a poor
Interestingly, the drop in IC50 value of diastereoisomerinhibitor of BHMT. Compound 5 is a natural tetrapeptide,
9a was even more dramatic, from 2.4 M to 1.0 M.without phosphinic moiety, with the sequence mimick-
Additionally, we found that L-methionine, one of theing that of compound 1. This peptide is a very weak
products of BHMT catalyzed reaction, is a rather weakinhibitor of BHMT when compared to compound 1, dem-
inhibitor of human recombinant BHMT with IC50 valueonstrating the importance of the phosphinate moiety for
of about 250 M. Compounds 9a and 9c are the mostthe recognition of compound 1 by BHMT. However, the
potent inhibitors of BHMT developed in this study andsole presence of a phosphinic pseudodipeptide moiety,
these compounds may be the most potent inhibitors ofas it is in the case of compound 6, is not sufficient for
BHMT published to date [37, 38].potent inhibition. Thus, the amino acids in the Xaa and
Xaa positions are key elements for insuring tight interac-
tion of the phosphinic pseudopeptide with BHMT. Prob- Discussion
ing the role of the N- or C-terminal protecting groups
provided interesting observations. Indeed, compound 7, Six of the proteins that were eluted from phosphinic
pseudopeptide affinity columns were identified as en-which bears a free carboxylate group in the C-terminus
instead of an amide group, did not inhibit BHMT at 100 zymes. Two of these enzymes, ECH and GST, were
eluted in a highly selective manner by phosphinic pseu-M concentration. This result is consistent with the abil-
ity of compound 1, when linked to the solid support by dopeptide mixtures in solution and very pure prepara-
tions of both enzymes were obtained (Figures 1A andits C-terminus (Figure 4A), to interact effectively with
BHMT. Finally, the removal of the N-acetyl group im- 1B, e.g., lines W-i and S-i). This means that the library
contained highly selective ligands for both enzymes.proved significantly the inhibitory potency (compound
8, Table 2). Compound 9, containing a pseudo-phenylal- Interestingly, attempts to determine if these phosphinic
peptides bind to the active site of GST and ECH failed.anine residue, is the most potent inhibitor of this series.
The four diastereoisomers of compounds 8 and 9 were The simplest explanation for this observation is to con-
sider that the binding sites for phosphinic pseudopep-resolved by RP-HPLC and tested to evaluate their po-
tency toward human BHMT. As shown in Table 3, among tides are outside of the active sites of these enzymes.
Table 3. Inhibition of Human BHMT by Individual Diastereoisomers of Compounds 8 and 9
IC50 (M)% of Inhibition
Compound 50 M pH 6.9 pH 7.5
8a Val-Ala-[PO2-CH2]-Leu-His-NH2 54.5 nd nd
8b Val-Ala-[PO2-CH2]-Leu-His-NH2 49.1 nd nd
8c Val-Ala-[PO2-CH2]-Leu-His-NH2 22.2 nd nd
8d Val-Ala-[PO2-CH2]-Leu-His-NH2 22.5 nd nd
9a Val-Phe-[PO2-CH2]-Leu-His-NH2 82.9 1.0 2.4
9b Val-Phe-[PO2-CH2]-Leu-His-NH2 44.2 9.0 12.0
9c Val-Phe-[PO2-CH2]-Leu-His-NH2 87.2 1.7 2.0
9d Val-Phe-[PO2-CH2]-Leu-His-NH2 64.8 3.7 5.0
L-Met nd nd 250
Inhibition potencies (at 50 M concentration) of individual diastereoisomers of compounds 8 and 9 towards human recombinant BHMT. The
IC50 values of individual diastereoisomers a–d of compound 9 and L-methionine towards human recombinant BHMT were determined in 50
mM K-phosphate buffer at two different pH. The diastereoisomers of pseudopeptides 8 and 9 are numbered a–d in the order they were eluted
by RP-HPLC. nd means not determined. For details, see Experimental Procedures.
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It would be of interest to confirm this hypothesis. As the capacity is probably due to the high preference of BHMT
for His amino acid in the Xaa position of pseudopeptides3D structures of both proteins are available [39, 40],
localization of binding sites on these enzymes could (Figure 3). In fact, His was only one of 19 amino acids
present in the Xaaposition of Ac-Ser-DL-Ala-[PO2-CH2]-also be possible by probing the protein surfaces with
phosphinic pseudopeptide structures. The selective in- DL-Leu-Xaa-(Ala)2-PL-PEGA affinity column containing
19 different pseudopeptides. This fact underscores theteraction of ECH and GST with our affinity columns could
be exploited for the development of selective affinity remarkable selectivity of Ac-Val-DL-Ala-[PO2-CH2]-
DL-Leu-His-AOA-Ala-Dap-Sepharose for BHMT.purification procedures for these enzymes.
Protein P8 was identified as 3-hydroxy-3-methylglu- Structure activity studies performed with Ac-Val-DL-
Ala-[PO2-CH2]-DL-Leu-His-NH2, which was obtainedtaryl-CoA synthase (EC 4.1.3.5), protein P13 as 3,2-
enoyl-CoA isomerase (EC 5.3.3.8), and protein P17 as L-3- by combinatorial approach (Figures 2 and 3), indicate
that the selectivity of the interaction between BHMThydroxyacyl-CoA dehydrogenase (EC 1.1.1.35). These
proteins, as well as ECH, are enzymes involved in the and this phosphinic pseudopeptide relies on several
structural features which are (1) the presence of themitochondrial/peroxisomal fatty acid metabolism. We
suppose that these enzymes could be retained on the phosphinate moiety, (2) the histidine residue, and (3) the
C-terminal carboxamide group (Tables 2 and 3).affinity columns as components of previously reported
multienzyme complex [26] through the interaction with Recently, the mechanism for the binding of homocys-
teine to the active site of a BHMT-related enzyme, methi-ECH.
Protein P9 was identified as rat elongation factor-1 . onine synthase, was defined [42, 43]. This mechanism
involves the formation of a zinc tetrathiolate complexAt present, we do not have a direct and rapid method
to prove the specific interaction of our inhibitors with formed by three cysteine ligands of the enzyme and the
thiolate group of the homocysteine substrate. It is likelythis protein involved in the proteosynthesis. However,
further investigation of this interaction could be interest- that similar mechanism occurs upon the binding of
homocysteine to the active site of BHMT where the Zn2ing because compounds interacting with elongation fac-
tor-1  display growth inhibitory effects on human tumor ion is also coordinated by 3 cysteine ligands [44]. This
hypothesis has recently been supported by the resolu-cells [41].
Protein P10 was identified as BHMT. Soluble phosphi- tion of a crystal structure of human BHMT in complex
with a transition state inhibitor [45]. We suppose thatnic pseudopeptide mixtures did not elute this protein
but GnCl treatment was necessary to release the protein the phosphinic inhibitors developed in this study interact
with the zinc atom of BHMT via their phosphinate groups,from the columns (Figure 1). Strikingly, in this case, sev-
eral observations lead us to conclude that the phosphi- that is, the phosphinates compete with homocysteine for
the enzyme’s catalytic Zn. This explanation is supportednic pseudopeptides interact with the active site of
BHMT. First, soluble phosphinic pseudopeptides were by our observation that homocysteine rather than beta-
ine could be used to effectively elute enzyme from theshown to inhibit BHMT activity. Second, homocysteine
and to a lesser extent betaine, the substrates of BHMT, phosphinate pseudopeptide column. The direct interac-
tion of phosphinate group oxygen atoms with a catalyticwere able to elute BHMT with high selectivity from the
affinity column grafted with the phosphinic pseudopep- zinc ion was recently proved by the resolution of the
structure of the complex between the metalloproteinasetide inhibitor Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His-
NH2 (Figure 4B). The more efficient elution of BHMT with astacine and a phosphinate inhibitor [22].
We demonstrated the successful application of a newhomocysteine compared to betaine suggests that the
phosphinic inhibitor occupies the homocysteine binding and simple method for the discovery of new protein
targets for artificial ligands of interest. Despite the verysite of BHMT tighter than the betaine binding site, if it
occupies the latter site at all. All major protein bands limited diversity of the pseudopeptide library (only 361
sequences) used, we isolated a large number of proteins(P21–P23) eluted from the affinity column with homocys-
teine are BHMT or BHMT-related enzymes. A weak band from which the majority was specifically retained on
affinity columns due to the presence of the pseudopep-of BHMT protein was observed in the inhibitor-eluted
fractions following the betaine/homocysteine washings. tides. N-terminal sequencing of twenty of these isolated
proteins resulted in the identification of BHMT, whichAlmost no protein was subsequently eluted from the
column using the nonspecific and denaturing agents, we subsequently showed to be selectively and relatively
potently inhibited by one of the pseudopeptides from theSDS and GnCl. The experiment shown in Figure 4 reveals
that Ac-Val-DL-Ala-[PO2-CH2]-DL-Leu-His-NH2 dis- library. Overall, we believe that this method, especially in
conjunction with 2D electrophoresis and MALDI massplays excellent selectivity for BHMT since it functioned
as an affinity ligand for the enzyme with such high speci- spectrometry, holds promise as an additional method
for the discovery of new specific protein-ligand interac-ficity that it could be used to purify the enzyme to homo-
geneity from a crude liver extract in single chromato- tions.
The phosphinic pseudopeptide inhibitors of BHMTgraphic step.
The densitometry analysis of the immunoblots re- developed in this study may be a very promising tool
for studying the physiological function of BHMT. Forvealed that the capacity of Ac-Ser-DL-Ala-[PO2-CH2]-
DL-Leu-Xaa-(Ala)2-PL-PEGA affinity column (5 moles example, in the absence of a mouse strain devoid of
BHMT activity, the design and use of selective inhibitorswas used) to capture 44 kDa BHMT was about 30 times
lower than the capacity of Ac-Val-DL-Ala-[PO2-CH2]- of this enzyme as drugs may help to elucidate whether
BHMT has an important role in the regulation of plasmaDL-Leu-His-AOA-Ala-Dap-Sepharose affinity column
(7 moles was used). The reason for this difference in homocysteine levels. This would be an important finding
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ately frozen at –72	C. All following procedures were carried out atsince hyperhomocysteinemia is believed to be a risk
4	C. When needed, rat livers (approximately 70 g) were thawed,factor for vascular diseases and thrombosis [46].
minced with scissors, and homogenized in the same volume of 25Our future effort will be focused on the synthesis and
mM Hepes/NaOH buffer (pH 7.5) containing 0.2 mM 1,4-dithiothreitol
characterization of phosphinate molecules of non-pep- (DTT) (buffer A) using a teflon glass homogenizer. The homogenate
tide nature mimicking the hypothetical transition state was centrifuged at 2400 g for 20 min. The supernatant was removed
and temporarily stored while the pellet was resuspended in halfoccurring upon binding of betaine and homocysteine to
volume of buffer A and centrifuged again as above. Then, boththe active site of BHMT.
supernatants were combined and centrifuged at 100,000 g for 65
min. The pellet was discarded and the resulting supernatant wasSignificance
diluted with buffer A to the final volume of 200 ml, divided into 20
equal portions, and immediately used for affinity chromatography
A new and simple approach for the discovery of novel or frozen at –72	C. The protein concentration was measured by the
procedure of Bradford [52] using bovine serum albumin as standardprotein targets for synthetic ligands is proposed. The
and was determined to be about 30 mg per ml.principle of a new method is based on combination of
affinity chromatography and combinatorial chemistry.
Affinity Chromatography on Immobilized PseudopeptideZn-metalloenzyme betaine: homocysteine S-methyl-
Libraries of General Formula Ac-Xaa-DL-Ala-[PO2-CH2]-DL-transferase (BHMT) was isolated from crude rat liver Leu-Xaa-(Ala)2-PL-PEGA
homogenate using affinity chromatography on sup- All steps were performed at 4	C. Before use, the individual affinity
ports with mixtures of immobilized phosphinic pseu- resins (5 moles of each) were placed into 2.5 ml plastic columns
with porous frits and connectors for tubings. The resins were thor-dopeptides. The respective soluble phosphinic pseu-
oughly washed with buffer A. Then, 10 ml of soluble rat liver homoge-dopeptides were then tested for their ability to inhibit
nate (RLH) were applied on each affinity column and allowed tohuman recombinant BHMT. We discovered potent and
circulate overnight at a flow rate of 0.5 ml per min. Thereafter, the
highly selective compounds, which can be effective affinity matrixes were washed with 20 ml of buffer A, 50 ml of 1.5
tools in a study of BHMT functions and properties. The M NaCl in buffer A, 10 ml of buffer A, 50 ml of 0.1% Triton X-100 in
results reported in this study validate the concept that buffer A, and 40 ml of buffer A. The bound proteins were at first
eluted from the affinity resins with 0.4 ml of 0.2 mM solution ofcombining combinatorial chemistry to affinity chroma-
respective soluble inhibitor mixtures in buffer A by slowly rotatingtography protocols makes possible to identify, without
the columns for 6 hr and then with 0.4 ml of 6 M GnCl in water forany a priori hypothesis, novel protein targets for phos-
4 hr. Ac-(Ala)2-PL-PEGA resin was eluted only with 6 M GnCl. Allphinic peptides. And vice versa, selective inhibitors fractions were analyzed by electrophoresis.
of BHMT were developed despite the rather limited
diversity of the phosphinic pseudopeptide library used Affinity Chromatography on Ac-Val-DL-Ala-[PO2-CH2]-DL-
Leu-His-AOA-Ala-Dap-Sepharoseto fish out the proteins. We believe that our new ap-
For the most part, these procedures were the same as describedproach can be a valuable tool in the search for the
above. The small differences are briefly described as follows. Ratfunction of the proteome.
liver homogenate (45 ml) was applied on affinity resin (7 mol) and
allowed to circulate for 6 hr. The bound proteins were eluted step-Experimental Procedures
wise from the affinity gel by slowly rotating for 6 hr in 0.7 ml of each
of following agents in buffer A: (1) 10 mM betaine (twice), (2) 1 mMFmoc-protected amino acids, Rink Amide AM resin, 2-Chlorotrityl
DL-homocysteine (three times), (3) 250 M Ac-Val-DL-Ala-[PO2-resin, Amino-PEGA resin, photolabile linker (PL, 4-[4-(1-amino-
CH2]-DL-Leu-His-NH2 (twice), (4) 1% SDS (twice), and (5) with 6 Methyl)-2-methoxy-5-nitro-phenoxy]-butyric acid) were purchased
GnCl (twice). Resin was washed with buffer A between differentfrom Novabiochem. NHS-activated Sepharose was purchased from
elutions. All fractions were analyzed by electrophoresis.Amersham Biosciences. Plastic columns for affinity chromatogra-
phy were from MoBiTec GmbH (Go¨ttingen, Germany). Anti-rabbit
Gel ElectrophoresisIgG peroxidase conjugated antibody, bovine liver ECH (crotonase),
SDS-PAGE was performed according to Laemmli [53] on 0.7 mmcrotonoylcoenzyme-A, glutathione, and 1-chloro-2,4-dinitroben-
thick gels (11% acrylamide in running gel, 5% acrylamide in stackingzene were purchased from Sigma-Aldrich. N-methyl-C14-betaine
gel). Proteins were visualized by silver staining procedure as de-was prepared and supplied by Moravek Biochemicals (Brea, CA).
scribed by Blum et al. [54]. The volume of 15 l was applied fromHuman recombinant BHMT and polyclonal antibodies against hu-
each fraction (0.4 ml or 0.7 ml). Fraction containing GnCl were dia-man recombinant BHMT were prepared as described previously
lyzed prior to the electrophoresis.[29, 47].
Western Blot AnalysisInhibitor and Affinity Support Synthesis
Samples were resolved by electrophoresis and electroblotted ontoThe soluble pseudopeptide library of general formula Ac-Xaa-DL-Ala-
PVDF membrane (Immobilon P, Millipore) at 2.5 mA/cm2 for 1.5 hr[PO2-CH2]-DL-Leu-Xaa-NH2 and single soluble pseudopeptides
using in 20 mM CAPS/NaOH buffer (pH 10.3) supplemented withwere prepared and characterized as described previously [18–20,
10% methanol and 0.01% SDS. All incubations and washes were48, 49]. The same methodology was applied for the synthesis of the
performed at room temperature with 20 mM Tris/HCl buffer (pHimmobilized library of general formula Ac-Xaa-DL-Ala-[PO2-CH2]-
7.5) supplemented with 140 mM NaCl and 0.1% Tween-20 (T-TBSDL-Leu-Xaa-(Ala)2-PL-PEGA and Ac-(Ala)2-PL-PEGA (blank resin)
buffer). Blocking was accomplished by incubating the membraneusing Amino-PEGA resin [14, 15]. Photolabile linker (PL) [50, 51] was
in 3% bovine serum albumine in T-TBS buffer (for 1 hr). The mem-introduced to allow the cleavage and the subsequent control of the
brane was then incubated for 30 min with a rabbit serum BHMTquality of synthesized structures. Ac-Val-DL-Ala-[PO2-CH2]-DL-
antibody, washed with T-TBS, and incubated for another 30 minLeu-His-AOA-Ala-Dap-Sepharose (AOA is 8-aminooctanoic acid,
with an anti-rabbit IgG peroxidase conjugated antibody in T-TBS.Dap is 1,3-diaminopropane) was prepared using NHS-activated
Before staining, the membrane was washed with T-TBS and thenSepharose as described elsewhere [16, 17].
developed with diaminobenzidine.
For N-terminal sequencing, the blotted proteins were stained inPreparation of Soluble Rat Liver Homogenate for Affinity
PVDF membrane with Coomassie Brilliant Blue R-250. Bands ofChromatography Procedures
interest were excised from a membrane and submitted to sequenc-Male Wistar rats weighing approximately 250 g were decapitated
and their livers were perfused with cold saline, excised, and immedi- ing on Perkin-Elmer Applied Biosystems 491 Protein Sequencer.
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Peptide sequences were submitted to various protein databases lian histone deacetylase related to the yeast transcriptional reg-
ulator Rpd3p. Science 272, 408–411.for identification [55].
10. Chen, J.K., Lane, W.S., and Schreiber, S.L. (1999). The identifica-
tion of myriocin-binding proteins. Chem. Biol. 6, 221–235.BHMT Assay
11. Nelson, R.W., Nedelkov, D., and Tubbs, K.A. (2000). BiosensorCompounds were tested for their ability to inhibit BHMT activity
chip mass spectrometry: a chip-based proteomics approach.(Tables 2 and 3) using an assay procedure we have described pre-
Electrophoresis 21, 1155–1163.viously in detail [56], with several modifications. Briefly, DL-
12. Baird, C.L., and Myszka, D.G. (2001). Current and emerginghomocysteine was freshly prepared by dissolving DL-homocysteine
commercial optical biosensors. J. Mol. Recognit. 14, 261–268.thiolactone hydrochloride (15.4 mg) in 400 l of 2 M NaOH. The
13. Stoll, D., Templin, M.F., Schrenk, M., Traub, P.C., Vohringer,solution was allowed to stand for 5 min at room temperature. The
C.F., and Joos, T.O. (2002). Protein microarray technology.solution was then neutralized by the addition of 600 l of a satu-
Front. Biosci. 7, C13–C32.rated solution of KH2PO4 and immediately used in BHMT assay. The
14. Meldal, M. (1992). PEGA: a flow stable polyethylene glycol di-standard BHMT assay (500 l) contained 0.7 M BHMT, different
methyl acrylamide copolymer for solid phase synthesis. Tetra-concentrations of inhibitor, 100M DL-homocysteine, 250M beta-
hedron Lett. 33, 3077–3080.ine (0.1 Ci N-methyl-C14-betaine was added into each reaction
15. Meldal, M., Auzanneau, F.-I., Hindsgaul, O., Palcic, M.M. (1994).mixture and the desired betaine concentration was adjusted with
A PEGA resin for use in the solid-phase chemical-enzymaticcold betaine), 10 mM -mercaptoethanol, and 50 mM Tris/HCl (pH
synthesis of glycopeptides. J. Chem. Soc. Chem. Commun.7.5). Human recombinant BHMT was first mixed with inhibitor(s)
1849–1850.then the substrates were added and the mixture incubated at 37	C
16. Tegge, W., and Frank, R. (1997). Peptide synthesis on Sepha-for 30 min. The reaction was stopped by transferring the reaction
roseTM beads. J. Pept. Res. 49, 355–362.tubes into ice water and by adding 2.5 ml of ice-cold water. The
17. Gast, R., Glo¨kler, J., Ho¨xter, M., Kiess, M., Frank, R., and Tegge,samples were applied to a Dowex 1 
 4 (200–400 mesh) and the
W. (1999). Method for determining protein kinase substratenon-reacted betaine was washed from the column with water. Di-
specificities by the phosphorylation of peptide libraries onmethylglycine and methionine were eluted into scintillation vials with
beads, phosphate-specific staining, automated sorting, and se-1.5 ml of 1.5 M HCl and then 8 ml of scintillation mixture were
quencing. Anal. Biochem. 276, 227–241.added to each vial and counted. Blanks contained all the reaction
18. Jiracek, J., Yiotakis, A., Vincent, B., Lecoq, A., Nicolaou, A.,components except enzyme and their values were subtracted from
Checler, F., and Dive, V. (1995). Development of highly potentthe sample values. All samples were assayed in triplicates and re-
and selective phosphinic peptide inhibitors of zinc endopepti-sults are expressed relative (%) to a sample containing no inhibitor.
dase 24–15 using combinatorial chemistry. J. Biol. Chem. 270,Inhibition curves for the determination of IC50 of inhibitors (Table
21701–21706.3) were measured in 50 mM K-phosphate buffer at pH 7.5 or 6.9
19. Jiracek, J., Yiotakis, A., Vincent, B., Checler, F., and Dive, V.using 0.2 M BHMT, 10 M DL-homocysteine, 50 mM betaine (0.5
(1996). Development of the first potent and selective inhibitor ofCi), and variable amounts of inhibitors. The inhibition at ten differ-
the zinc endopeptidase neurolysin using a systematic approachent inhibitor concentrations was determined for each curve. All sam-
based on combinatorial chemistry of phosphinic peptides. J.ples were assayed in duplicates and each curve was measured
Biol. Chem. 271, 19606–19611.twice.
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